IL133176A0 - Pharmaceutical compositions of peptides having low solubility in physiological medium - Google Patents

Pharmaceutical compositions of peptides having low solubility in physiological medium

Info

Publication number
IL133176A0
IL133176A0 IL13317698A IL13317698A IL133176A0 IL 133176 A0 IL133176 A0 IL 133176A0 IL 13317698 A IL13317698 A IL 13317698A IL 13317698 A IL13317698 A IL 13317698A IL 133176 A0 IL133176 A0 IL 133176A0
Authority
IL
Israel
Prior art keywords
peptides
pharmaceutical compositions
low solubility
physiological medium
physiological
Prior art date
Application number
IL13317698A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL133176A0 publication Critical patent/IL133176A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13317698A 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium IL133176A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
IL133176A0 true IL133176A0 (en) 2001-03-19

Family

ID=26145485

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13317698A IL133176A0 (en) 1997-05-28 1998-05-26 Pharmaceutical compositions of peptides having low solubility in physiological medium
IL133176A IL133176A (en) 1997-05-28 1999-11-28 Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL133176A IL133176A (en) 1997-05-28 1999-11-28 Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium

Country Status (27)

Country Link
US (1) US6331520B1 (no)
EP (2) EP0880969A1 (no)
JP (1) JP2002502384A (no)
KR (1) KR100552546B1 (no)
CN (1) CN1159062C (no)
AR (1) AR012868A1 (no)
AT (1) ATE252909T1 (no)
AU (1) AU743152B2 (no)
BG (1) BG64668B1 (no)
BR (1) BR9809708A (no)
CA (1) CA2291765A1 (no)
CZ (1) CZ298825B6 (no)
DE (1) DE69819322T2 (no)
DK (1) DK0984788T3 (no)
EA (1) EA002227B1 (no)
EE (1) EE04001B1 (no)
ES (1) ES2210772T3 (no)
HK (1) HK1029928A1 (no)
IL (2) IL133176A0 (no)
NO (1) NO323697B1 (no)
NZ (1) NZ500777A (no)
PL (1) PL192647B1 (no)
PT (1) PT984788E (no)
SI (1) SI0984788T1 (no)
SK (1) SK284640B6 (no)
TR (1) TR199902865T2 (no)
WO (1) WO1998053844A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
JP2010523501A (ja) * 2007-04-04 2010-07-15 セラテクノロジーズ インコーポレイティド Ghrh分子の医薬製剤
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
CN104918927B (zh) * 2012-10-12 2018-09-07 莱雅公司 含有至少一种水溶助长剂和至少一种活性化合物的化妆品组合物
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
CA3014406A1 (en) 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
CN112839632A (zh) 2018-09-20 2021-05-25 莱沃疗法公司 稳定的鼻内卡贝缩宫素制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
AU641721B2 (en) * 1989-12-21 1993-09-30 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
TW280770B (no) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
AU8106298A (en) 1998-12-30
SK284640B6 (sk) 2005-08-04
EE04001B1 (et) 2003-04-15
CZ298825B6 (cs) 2008-02-20
US6331520B1 (en) 2001-12-18
PL336982A1 (en) 2000-07-31
EP0880969A1 (en) 1998-12-02
IL133176A (en) 2006-08-01
DK0984788T3 (da) 2004-03-08
CZ423199A3 (cs) 2000-05-17
CN1263469A (zh) 2000-08-16
KR100552546B1 (ko) 2006-02-14
BG64668B1 (bg) 2005-11-30
ATE252909T1 (de) 2003-11-15
JP2002502384A (ja) 2002-01-22
SK159799A3 (en) 2000-07-11
PL192647B1 (pl) 2006-11-30
WO1998053844A1 (en) 1998-12-03
NO323697B1 (no) 2007-06-25
DE69819322T2 (de) 2004-07-29
EP0984788B1 (en) 2003-10-29
SI0984788T1 (en) 2004-02-29
DE69819322D1 (de) 2003-12-04
NZ500777A (en) 2001-09-28
CA2291765A1 (en) 1998-12-03
PT984788E (pt) 2004-01-30
CN1159062C (zh) 2004-07-28
EP0984788A1 (en) 2000-03-15
KR20010012253A (ko) 2001-02-15
AU743152B2 (en) 2002-01-17
NO995763D0 (no) 1999-11-24
EA002227B1 (ru) 2002-02-28
AR012868A1 (es) 2000-11-22
NO995763L (no) 1999-11-24
HK1029928A1 (en) 2001-04-20
TR199902865T2 (xx) 2000-05-22
BR9809708A (pt) 2000-07-11
EA199901089A1 (ru) 2000-06-26
EE9900545A (et) 2000-06-15
ES2210772T3 (es) 2004-07-01
BG103884A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
HUP0003761A2 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
HUP9701018A3 (en) Xantine derivatives having (omega-amino)-hydroxyalkynyl side-chain and pharmaceutical compositions containing them
HUP0001269A3 (en) 2-oxo-1-azetidine sulfonic acid derivatives and combined pharmaceutical compositions thereof
IL114925A (en) Glycinamide derivatives their preparation and pharmaceutical compositions containing them
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
IL133176A0 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
IL124661A0 (en) 5'-Deoxy-cytidine derivatives their preparation and pharmaceutical compositions containing them
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
ZA9811655B (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
IL125908A (en) Peptides and pharmaceutical compositions comprising same
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
ZA982952B (en) Pseudo-peptide compounds their preparation and use in pharmaceutical formulations
HUP0002118A3 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
ZA984469B (en) Pharmaceutical compositions of peptides having low solubility of physiological medium
HK1016590A1 (en) Pharmaceutical compositions comprising famciclovir monohydrate
HUP0500956A3 (en) Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them
HUP0102705A3 (en) Alpha-amino acid phenyl ester derivatives and their use and pharmaceutical compositions comprising them
IL123429A0 (en) Peptides and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees